LEUPROLIDE ACETATE

Synonyms. Leuprorelin acetate; des-Gly10-[D-Leu6]-LH-RH ethylamide; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl- L-seryl-L- tryosyl- D-leucyl- L- leucyl- L-arginyl-N-ethyl-L-prolinamide monoacetate; Leuprorelin acetate; Glp-His-Trp-Ser-Tyr-Leu-Leu-Arg-Pro-NHEt; Lucrin; Lupron; Procrin; Viadur; Eligard; Enantone;

LEUPROLIDE

 

PRODUCT IDENTIFICATION

CAS RN

53714-56-0 (parent), 74381-53-6 (Acetate)

EINECS RN

256-342-8, 232-693-2 

FORMULA

C59H84N16O14

MOLE WEIGHT

1241.40

H.S CODE

 2937.19.0000

SMILES

 c1cc2c(cc1)c(C[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](Cc1ccc(cc1) O)C(N[C@@H](C(N[C@H](C(=O)N[C@H](C(N1CCC[C@H]1C(=O)NCC)= O)CCCNC(N)=N)C(C)C)=O)C(C)C)=O)CO)NC ([C@H](Cc1[nH]cnc1)NC([C @@H]1NC(CC1)=O)=O)=O) c[nH]2.OC(C)=O

CLASSIFICATION

Antineoplastic, Fertility Agent

EXTRA NOTES

 A potent synthetic long-acting agonist of gonadotropin-releasing hormone that regulates the synthesis and release of pituitary gonadotropins, luteinizing hormone and follicle stimulating hormone

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE.

white powder

MELTING POINT

 

BOILING POINT

 

DENSITY

 

SOLUBILITY IN WATER

 

SOLVENT SOLUBILITY  

VAPOR DENSITY

 

log P(octanol-water)

  

VAPOR PRESSURE

  

AUTOIGNITION TEMP

  
pH

 

REFRACTIVE INDEX

 

FLASH POINT

 

 
STABILITY AND REACTIVITY
STABILITY Stable under normal conditions.

INCOMPATIBLE MATERIALS

Strong acids, Strong bases

POLYMERIZATION

Has not been reported

NFPA RATINGS

Health: 2,Flammability:0, Reactivity: 0

 

EXTERNAL LINKS & GENERAL DESCRIPTION

Leuprolide: The active ingredient in a drug used to treat symptoms of advanced prostate cancer. It is also used to treat early puberty in children and certain gynecologic conditions. It is being studied in the treatment of other conditions and types of cancer. Leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. It is a type of gonadotropin-releasing hormone analog. (http://www.cancer.gov/)

Leuprolide is FDA approved for the treatment of advanced prostate cancer. It is important for patients to remember that physicians have the ability to prescribe medication for conditions other than those for which the drug has been approved by the FDA. Patients who have received a prescription of this drug for a condition other than which it is approved may wish to discuss this issue with their physician. Leuprolide is classified as a luteinizing hormone releasing hormone (LHRH) agonist. LHRH is a naturally occurring hormone in the body that is involved in stimulating the production of female and male hormones such as estrogen and testosterone. Leuprolide inhibits the signaling of LHRH so that the production of estrogen or testosterone is reduced. Certain cancers, such as prostate cancer, are stimulated to grow from hormones. The reduction in the production of growth-stimulatory hormones inhibits the growth of cancer cells. (http://www.ufscc.ufl.edu/)

Leuprolide is a luteinizing hormone releasing hormone (LHRH) agonist. It is a synthetic analog of LHRH (also known as gonadotropin releasing hormone [GnRH]).3 LHRH agonists (LHRHa) initially stimulate the release of luteinizing hormone (LH, gonadotropin), resulting in a transient elevation in serum androgen in men and serum estradiol in women. However, chronic administration can cause down-regulation of the LHRH receptors, thus inhibiting the secretion of LH and ultimately the sex hormones (androgen, estradiol). By decreasing the testicular production of androgen in men, LHRHa can inhibit the growth of androgen-dependent prostate cancer. Similarly, LHRHa reduce the ovarian secretion of estradiol and progesterone in women,4 leading to inhibition of estrogen-dependent cancers. In men, LHRHa can reduce serum androgen to castrate level. Similarly, in pre-menopausal women, serum estradiol level is reduced to post-menopausal levels. These decreases occur within two to four weeks after initiation of treatment, and are maintained as long as treatment continues. LHRHa are 50-100 times more potent than LHRH.5 In addition, they have a longer duration of action due to increased receptor affinity and greater biological stability. (http://www.bccancer.bc.ca/)

 

SALES SPECIFICATION

APPEARANCE

 white to off-white powder
MASS BALANCE 97.0~103.0%

PURITY

98.0% min
AMINO ACID 10% max (theoretical Composition)

RELATED SUBSTANCES

2.0% max (total impurity)
PEPTIDE CONTENT
80.0% min (N determination)
ACETATE CONTENT

12.0% max
WATER CONTENT 6.0% max
BACTERIAL ENDOTOXINS 5EU/mg max

 

TRANSPORT & REGULATORY INFORMATION

UN NO.

Not known

HAZARD CLASS

  
PACKING GROUP  

 

SAFETY INFORMATION

HAZARD OVERVIEW

Reproductive hazard. Not a dangerous substance according to GHS

HAZARD CODES

 

RISK PHRASES

  

SAFETY PHRASES

 26

 

PACKING